References

More information about references found on this website.

 

  1. A la suite de la fusion en mai 2013 entre Intercell AG et SA Vivalis pour former Valneva SE, les résultats 2018 et 2013 du Groupe ne sont pas entièrement comparables. Les résultats de VIVALIS SA ont été entièrement inclus dans le compte de résultat de 2013 alors que les résultats de Intercell ont été seulement inclus pour la période de sept mois à compter de Juin 2013.
  2. Comprend les revenus de services et des accords de licence.
  3. As of December 31
  4. Communiqué de presse Valneva: https://www.valneva.com/en/investors-media/news/2019#4010
  5. Communiqué de presse Valneva: https://www.valneva.com/en/investors-media/news/2019#4014
  6. How many people get Lyme disease? | Lyme Disease | CDC. (n.d.). Retrieved from https://www.cdc.gov/lyme/stats/humancases.html
  7. Estimated from available national data. Number largely underestimated based on WHO Europe Lyme Report as case reporting is highly inconsistent in Europe and many LB infections go undiagnosed; ECDC tick-borne-diseases- meeting-report
  8. Stanek et al. 2012, The Lancet 379: 461-473
  9. New Scientist, Lyme disease is set to explode and we still don’t have a vaccine; March 29, 2017, https://www.newscientist.com/article/mg23431195-800-lyme-disease-is-set-to-explode-and-you-cant-protect-yourself
  10. Communiqué de presse Valneva: https://www.valneva.com/en/investors-media/news/2018#303
  11. Communiqué de presse Valneva: https://www.valneva.com/en/investors-media/news/2018#282
  12. Aucune différence dans le profil de sécurité ont été observées pour les groupes adjuvantés par rapport aux groupes de traitement non adjuvantés
  13. IgG levels were substantially higher after three immunizations (Day 84) compared to after two (Day 56)
  14. Communiqué de presse Valneva: https://www.valneva.com/en/investors-media/news/2017#270
  15. Factsheet Chikungunya. Retrieved from https://www.paho.org/hq/index.php?option=com_content&view = article&id=8303:2013-hoja-informativa-chikungunya&Itemid = 40023&lang = fr
  16. PAHO/WHO data: Number of reported cases of chikungunya fever in the Americas – EW 51 (December 22, 2017). Retrieved from https://www.paho.org/hq/dmdocuments/2017/2017-dec-22-phe-CHIKV-cases-ew-51.pdf
  17. Cardona-Ospina et al., Trans R Soc Trip Med Hyg 2015
  18. Communiqué de presse Valneva: https://www.valneva.com/en/investors-media/news/2019#305
  19. Communiqué de presse Valneva: https://www.valneva.com/en/investors-media/news/2018#304
  20. Hallengärd et al. 2013 J. Virology 88: 2858-2866
  21. Provisional Data as of January 2, 2019, https://www.cdc.gov/zika/reporting/case-counts.html
  22. Communiqué de presse Valneva: https://www.valneva.com/en/investors-media/news/2018#300
  23. Lessa et al, Burden of Clostridium difficile Infection in the United States. N Engl J Med 2015;372:825-34
  24. Dubberke ER, Clinical Infectious Diseases 55, no. suppl 2 (2012): S88-S92.
  25. Magill S, Edwards J R, Bamberg W et al. Multistate Point-Prevalence Survey of Health Care–Associated Infections. New England Journal of Medicine 2014;370:1198-208
  26. Lessa et al, Burden of Clostridium difficile Infection in the United States. N Engl J Med 2015;372:825-34
  27. Lessa et al, Clostridium difficile infection. N Engl J Med 2015;372:1539-48).